MB Endobiomedika Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2023 |
|---|
| 15,393 |
| - |
| 15,393 |
| 9,281 |
| - |
| 100.00 |
| 60.29 |
| 9,281 |
| 673 |
| 0 |
| 9,954 |
| 0.60 |
| 0.07 |
| - |
| - |
| 100.00 |
| 15,393 |
| 2024 |
|---|
| 14,356 |
| - |
| 5,690 |
| 5,405 |
| - |
| 100.00 |
| 37.65 |
| 14,686 |
| 3,315 |
| 0 |
| 18,001 |
| 1.02 |
| 0.23 |
| - |
| - |
| 39.63 |
| 5,690 |
| 2025 |
|---|
| 13,245 |
| - |
| 5,750 |
| 5,750 |
| - |
| 100.00 |
| 43.41 |
| 20,436 |
| 424 |
| 0 |
| 20,860 |
| 1.54 |
| 0.02 |
| - |
| - |
| 43.41 |
| 5,750 |
| 2025 |
|---|
| 13,245 |
| - |
| 5,750 |
| 5,750 |
| - |
| 100.00 |
| 43.41 |
| 20,436 |
| 424 |
| 0 |
| 20,860 |
| 1.54 |
| 0.02 |
| - |
| - |
| 43.41 |
| 5,750 |
Turnover (€)
2025
Turnover (€)
13,245 €-8 % *
Sales per employee (€)
-Profit before tax (€)
5,750 €1 % *
Net Profit (€)
5,750 €6 % *
Profit per employee (€)
-Total profitability (%)
100.00 %0.00 % *
Net profitability (%)
43.41 %15.30 % *
Equity (€)
20,436 €39 % *
Amounts Payable And Liabilities (€)
424 €-87 % *
Non-current Assets (€)
0 €- *
CurrentAssets (€)
20,860 €16 % *
Working capital requirement
1.54 50.98 % *
Debt-to-equity ratio
0.02 -91.30 % *
EBITDA margin (%)
-EBITDA (€)
-EBIT margin (%)
43.41 %9.54 % *
EBIT (€)
5,750 €1 % *
